ClearPoint Neuro pays director fees with 319 shares
ClearPoint Neuro, Inc. director Timothy T. Richards received 319 shares of common stock on October 1, 2026, as payment of fees owed under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan and Non-Employee Director Compensation Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ClearPoint Neuro, Inc. director Timothy T. Richards received 319 shares of common stock on October 1, 2026, as payment of fees owed under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan and Non-Employee Director Compensation Plan. The shares were issued at the common stock’s September 30, 2026 closing price of $12.21 per share. His reported direct holdings following the issuance were 87,863 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 319 | $12.21 | $4K |
Footnotes (1)
- F1. These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026.
Key Figures
Key Terms
Seventh Amended and Restated 2013 Incentive Compensation Plan financial
Non-Employee Director Compensation Plan financial
closing price market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.